AI in Oncology Market Report Scope & Overview:

The AI in Oncology Market was valued at USD 4.43 Billion in 2025 and is expected to reach USD 54.71 Billion by 2035, growing at a CAGR of 26.23% from 2026 to 2035.

Cancer care is becoming steadily more complex, and that complexity is exactly what's pulling artificial intelligence deeper into oncology workflows. Physicians are under growing pressure to diagnose faster, personalize treatment more precisely, and manage larger patient caseloads without sacrificing accuracy, and AI tools are increasingly filling that gap across imaging, pathology, genomics, and clinical decision support. Hospitals and cancer centers are integrating AI into radiology and pathology systems to catch tumors earlier and reduce diagnostic error, while pharmaceutical companies are leaning on AI to speed up drug discovery and clinical trial recruitment. That combination of clinical need and technical maturity is what's driving such an unusually fast growth trajectory for this category compared with most other healthcare technology markets.

More than 20 million new cancer cases are diagnosed globally each year, with lung cancer remaining the leading cause of cancer death, and AI-based image analysis programs are now achieving diagnostic accuracy above 90% in image-based cancer detection. In May 2025, DeepScribe partnered with Flatiron Health to deliver ambient AI documentation tools tailored for oncology to more than 4,200 providers across Flatiron's clinical network.

Market Size and Forecast

• Market Size in 2026E: USD 5.59 Billion

• Market Size by 2035: USD 54.71 Billion

• CAGR: 26.23% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

To Get more information on AI in oncology Market - Request Free Sample Report

AI in Oncology Market Trends

• Rising adoption of AI-driven diagnostic tools is improving early cancer detection and enabling more personalized treatment planning.

• Growing integration of genomics, imaging, and clinical data is helping deliver truly precision-based oncology care.

• Demand for AI-powered clinical trial optimization and patient recruitment platforms keeps expanding across pharmaceutical R&D.

• AI-based radiology and pathology solutions are expanding rapidly across hospitals and dedicated cancer centers.

• Healthcare providers and pharmaceutical companies are stepping up investment in AI research and development.

• Collaborations between AI startups and major healthcare institutions are accelerating the pace of oncology innovation.

• Government initiatives and increasingly supportive regulation are fostering broader AI adoption in cancer diagnostics and treatment planning.

The U.S. AI in Oncology Market Outlook

The U.S. AI in Oncology Market was valued at approximately USD 1.38 Billion in 2025 and is expected to reach approximately USD 8.26 Billion by 2035, growing at a CAGR of approximately 25.17%.

The U.S. leads the global AI in oncology market on the strength of a deep AI R&D ecosystem, supportive federal policy, and early adoption at leading cancer centers. Institutions like MD Anderson and Memorial Sloan Kettering have integrated AI deeply into diagnostics, radiology, and digital pathology workflows, and that institutional leadership keeps pulling in further investment and cross-border technology partnerships that reinforce the country's position at the center of oncology AI innovation.

The U.S. carries an oncology-focused AI research ecosystem worth more than USD 48 billion, supported by the FDA's Software Precertification Program, and Azra AI launched an enhanced platform in 2025 combining genomic profiling with real-world patient data to speed up clinical trial enrollment and personalize treatment recommendations.

AI in Oncology Market Segmentation Analysis

• By Component Type, the hardware segment dominated the AI in oncology market with approximately 40.2% share in 2025, while the software solutions segment is the fastest growing.

• By Cancer Type, the breast cancer segment dominated the AI in oncology market with approximately 21.3% share in 2025, while the prostate cancer segment is the fastest growing.

• By Application, the diagnostics segment dominated the AI in oncology market with approximately 37.3% share in 2025, while the chemotherapy segment is the fastest growing.

• By End Use, the hospitals segment dominated the AI in oncology market with approximately 49.3% share in 2025, while the surgical centers & medical institutes segment is the fastest growing.

By Component Type, hardware dominates, software solutions grow fastest

Hardware led the component type segment in 2025, accounting for approximately 40.2% of AI in oncology market revenue. That leadership reflects how much high-performance computing infrastructure oncology AI genuinely depends on, since processing complex imaging datasets, genomic sequences, and multi-omics data in real time requires serious GPU capacity, specialized AI chips, and edge computing devices rather than standard hospital IT equipment. Hospitals and research centers have been investing heavily in AI-ready imaging equipment and expanded data storage systems to support this infrastructure, and that capital spending has kept hardware at the top of the component mix even as software capability continues to advance. Without the underlying computing power, even the most sophisticated diagnostic algorithms simply can't run fast enough to be clinically useful, which keeps hardware demand tightly coupled to broader AI oncology adoption.

Software solutions are expected to be the fastest-growing component category through 2035, as AI algorithms become more tightly woven into diagnostic platforms, clinical workflow tools, and decision support systems used across cancer centers. Cloud-based AI software capable of analyzing genomics and radiomics data together is seeing particularly strong uptake, since it lets oncologists pull multiple data types into a single predictive model rather than reviewing each dataset separately. That shift toward integrated, cloud-native software is proving especially attractive to mid-sized hospitals that can't justify heavy hardware investment but still want access to advanced AI capability, which is helping widen the addressable market for software vendors well beyond the largest academic cancer centers. Subscription-based software licensing models are also lowering the barrier to entry further, letting smaller institutions adopt sophisticated diagnostic algorithms without the capital expenditure that hardware ownership typically demands.

By Cancer Type, breast cancer dominates, prostate cancer grows fastest

Breast cancer held the largest cancer type share in 2025, at roughly 21.3%, driven by the sheer scale of mammography and digital breast tomosynthesis screening programs that AI algorithms now support for earlier detection and more accurate classification. Breast cancer screening benefits from decades of public awareness campaigns and well-established screening infrastructure in most developed healthcare systems, which has produced enormous volumes of imaging data that AI models can be trained and validated against. That data advantage, combined with high patient screening volumes and strong reimbursement support for mammography-based diagnostics, has made breast cancer the natural first application for many AI vendors entering the oncology imaging space, reinforcing its lead position within the broader cancer type segmentation.

Prostate cancer will be the leading-growing type of cancer, fueled by increasing adoption of AI-powered MRI interpretation and biopsy optimization. AI tools are becoming highly effective in the precise tumor localization and patient risk stratification, significantly facilitating medical decisions about active surveillance or intervention in case of prostate cancer. The advances were demonstrated by the team from Vanderbilt University Medical Center at an AI-powered oncology conference during AACR 2025, showcasing just how fast deep learning technologies are being integrated into the field of prostate imaging in particular. Lung cancer and colorectal cancer are also receiving significant investments in AI due to the importance of early diagnosis in these cancers, yet none of them are narrowing the growth gap with respect to prostate cancer. With the increasing adoption of AI-powered biopsy planning and risk stratification for prostates by urology departments, the segment will continue to outpace the overall cancer type segment well until 2035.

By Application, diagnostics dominates, chemotherapy grows fastest

In 2025, the leading AI oncology application would be diagnostics, comprising almost 37.3% of the entire market revenue. This trend can be explained by the constant need for precision and highly efficient tools able to detect cancer on both the point-of-care level and through screening programs. Currently, AI-aided radiology and pathology solutions are reducing the time needed to detect cancer and decreasing the possibility of mistakes, allowing physicians to detect tumors at an earlier stage than it is possible without artificial intelligence. Since the accuracy of diagnostics influences the outcome of the treatment, healthcare organizations prefer to invest in diagnostics before other oncology applications. At the same time, radiation therapy and research & development applications are also experiencing consistent growth, although they do not reach the volume of the diagnostic imaging segment.

Chemotherapy is projected to be the fastest-growing application, as AI tools increasingly help tailor drug dosing, predict toxicity, and assess how individual patients are responding to treatment in near real time. That capability lets oncologists personalize chemotherapy regimens more precisely and cut down on the trial-and-error adjustment that used to characterize much of chemotherapy management, reducing avoidable side effects and improving overall patient experience. As more cancer centers adopt AI-driven treatment response monitoring alongside traditional chemotherapy protocols, this application is expected to grow considerably faster than the broader application category, reflecting a genuine shift toward AI-assisted treatment optimization rather than purely diagnostic use cases. Immunotherapy is following a similar trajectory, with AI increasingly used to predict which patients are most likely to respond to specific immune-based treatments before therapy even begins.

By End Use, hospitals dominate, surgical centers & medical institutes grow fastest

The hospitals held the largest market share in the end-use segment, accounting for 49.3% of the market in 2025 owing to the key role played by hospitals in terms of being the most common place for diagnosing and treating cancer, as well as undergoing surgery in relation to the disease. The reason why hospitals have been the earliest and biggest adopters of such AI technologies as image analysis, diagnostics, and treatment planning is that hospitals tend to see the greatest number of complicated oncology patients, which justifies the costs needed for such an infrastructure.

Surgical centers and medical institutes are projected to post the highest growth rate among end-use settings, driven by rising demand for AI-powered robotic surgery systems, AI-enhanced intraoperative imaging, and precision oncology platforms tailored to surgical decision-making. These specialized settings tend to adopt emerging technology faster than general hospitals, partly because of their narrower clinical focus and partly because of heavier involvement in clinical research programs that pilot new AI tools before broader rollout.

Regional Analysis

North America AI in Oncology Market Insights

North America commanded the largest share of the global AI in oncology market in 2025, supported by high healthcare digitization, a dense concentration of leading AI oncology companies, and early adoption of AI-enabled precision medicine across the region's most advanced hospitals and cancer centers. Advanced healthcare systems throughout the U.S. and Canada are leveraging AI for diagnostics, treatment planning, and clinical research simultaneously, which has accelerated adoption well beyond what isolated pilot programs typically achieve. Rising investment in AI startups, paired with deepening partnerships between technology firms and healthcare institutions, continues to reinforce that regional lead, and cross-border collaboration is gradually extending AI-based oncology capability into Mexico as well, broadening the region's overall footprint.

The United States is the dominant country within North America's AI in oncology market, valued at approximately USD 1.38 Billion in 2025 and accounting for roughly 80% of regional revenue. That leadership rests on a robust AI R&D ecosystem exceeding USD 48 billion in oncology-focused research spending, supportive government policy including the FDA's Software Precertification Program, and widespread integration of AI across leading cancer centers such as MD Anderson and Memorial Sloan Kettering. These factors together create an unusually strong adoption environment for AI platforms across diagnostics, radiology, and digital pathology, and that combination of capital, policy support, and institutional leadership is what keeps the U.S. as the clear regional leader in oncology AI. Canada is following a comparable path on a smaller scale, with several major teaching hospitals piloting similar AI diagnostic tools in partnership with U.S.-based technology vendors.

Get Customized Report as per Your Business Requirement - Enquiry Now

Europe AI in Oncology Market Insights

Europe was the second-largest contributor to the global AI in oncology market in 2025 due to strong national healthcare systems, EU-wide medical device regulation, and collaborative research programs like Horizon Europe, which provides funding for cross-border use of AI in healthcare. AI implementation in hospital oncology care in Europe proceeds steadily, leading to tangible benefits in terms of efficiency and clinical results in the most advanced cancer centers, especially those located in countries with high-budget public healthcare systems capable of covering initial expenses related to AI integration. Standardized EU medical devices regulation also facilitates the process of implementing a single certified AI oncology product in multiple national markets instead of obtaining separate certifications in each of them, gradually increasing the speed of regional AI oncology market growth.

Germany dominates Europe's AI in oncology market, accounting for roughly 27% of regional revenue, supported by its well-established medical device industry, active AI integration in radiotherapy planning, and strong collaborative relationships between healthcare providers and AI technology companies. That collaborative model has meaningfully improved clinical accuracy and expanded research capability across German cancer centers, and it continues to serve as something of a template for AI adoption elsewhere in Europe. France, the UK, and Italy are all following a similar trajectory, gradually building out AI-enabled diagnostic and treatment planning infrastructure across their national cancer care systems, while Poland, Spain, and Turkey represent earlier-stage but steadily growing markets within the broader European region, gradually catching up as EU-wide digital health funding continues to flow toward smaller member states.

Asia Pacific AI in Oncology Market Insights

Asia Pacific is expected to register the fastest CAGR in the global AI in oncology market through 2035, fueled by rising cancer prevalence, government-backed AI initiatives, rapidly expanding digital health infrastructure, and growing need for improved diagnostic accuracy across countries with large, underserved patient populations. Increasing adoption of AI-assisted surgical oncology and precision medicine platforms is driving much of that expansion, particularly as governments across the region prioritize healthcare digitization as part of broader economic modernization programs that touch nearly every major industry, not just healthcare specifically. Rapidly growing middle-class populations across Southeast Asia are also adding to regional demand, as rising disposable income widens access to private hospital networks that are often the first to adopt new diagnostic technology.

China has clearly established itself as the regional leader, backed by an aggressive national-level AI strategy along with large-scale adoption of AI technologies in hospital settings, with the overall health AI market valued at more than USD 10 billion in 2024. Some of the biggest tech companies in China such as Tencent and Alibaba are rolling out oncology-specific AI technologies in the Chinese hospital setting, strengthening the country's reputation as the leader in innovation in the region. Similarly, other countries in the region such as India, Japan, and South Korea are rapidly advancing their AI technologies with the help of precision oncology centers, surgical robotics, and machine learning techniques, thereby making the regional momentum for AI growth likely to keep Asia Pacific well ahead of the rest of the world in terms of growth up to 2035.

MEA & Latin America AI in Oncology Market Insights

MEA was a consistent adopter of AI in oncology applications in 2025 due to growing digital health efforts, government collaborations, and investments made in AI health infrastructure in the Gulf States. Both Saudi Arabia and the UAE have launched pilot AI-enabled oncological diagnosis and treatment applications under their efforts to improve the healthcare systems within their jurisdictions. This move has helped promote AI capability in oncology in the region, which has not been as advanced as North America, Europe, and Asia Pacific in healthcare technological advancements. Approximately 28% of MEA regional revenue is generated in Saudi Arabia, while Qatar and South Africa are following a similar model of early adoption of AI oncology.

Latin America is growing more gradually, led by Brazil and Mexico, where hospital-based AI projects in radiology and oncology are steadily expanding. Brazil leads regional revenue at roughly 42%, and growing AI infrastructure investment, new regional partnerships, and rising awareness of precision oncology solutions are all enhancing the market for AI-driven oncology tools across the wider region. Argentina is emerging as a secondary market as its private hospital networks begin piloting similar diagnostic AI tools, often in partnership with academic research centers. While adoption in both MEA and Latin America still trails the world's more mature markets, the direction of travel is clearly toward greater AI integration, and continued government and private investment is expected to narrow that gap further through 2035.

Growth Drivers: Rising demand for precision oncology and AI-driven clinical tools

Increasing complexity in the provision of cancer treatment, increasing prevalence of personalized treatment strategies, and rising need for fast and precise diagnosis collectively fuel growth in the global artificial intelligence in oncology market. Cancer diagnosis has been revolutionized by the AI algorithms, which now offer an unparalleled 95% accuracy in malignancy detection in CT and PET scans, and reduce time spent on diagnosis more than 50% in comparison to the manual radiologist analysis only. The electronic health records of hospitals are becoming increasingly equipped with the integrated AI-based clinical decision support system incorporated into oncology workflows, the use of which increased 42% in the last three years from 2021 to 2024 in comprehensive cancer centers. Using multi-omics and real-world data along with patient's own genomics allows oncologists to develop personalized treatment protocols impossible to establish manually with high precision.

Demand is further boosted by rising R&D expenditure, with global AI investment in cancer-related clinical trials growing 4.7 times over the last six years alone. Regulatory backing has strengthened this momentum too, with more than 30 cancer-related AI devices receiving FDA authorization to use AI between 2019 and 2024, while organizations such as CDSiC and ASCO have published prescriptive guidelines supporting ethical AI use in oncology practice. Funding support has followed accordingly, with AI drug discovery platforms alone attracting more than USD 2.3 billion in investment in 2023. The accelerating need to reduce physician burnout and decision fatigue has further reinforced reliance on AI for treatment planning and radiology reporting, an evolution that continues to sustain the expanding AI in oncology market.

Restraints: Data privacy, infrastructure gaps, and clinical validation challenges

The privacy of data is still the major challenge facing the current market, since 85% of healthcare administrators consider HIPAA and GDPR compliance as the major challenges to the use of AI. AI systems require large amounts of good quality data for successful implementation. However, there is an issue of poor interoperability of fragmented electronic health records and non-standardized cancer registries, which hinder smooth transfer of data between institutions and across countries. According to the study conducted in 2023, the accuracy of tumor detection was 21% lower in populations that are underrepresented because the AI system is trained on a dataset that does not have diverse demographics.

Based on the study carried out in 2023, the accuracy of the diagnosis was 21% lower in underrepresented populations as the AI technology uses a data set that does not contain diverse demographics. Clinical validation of the technology has also been far from complete across the industry as only 12% of the oncology AI technologies currently undergoing clinical trials have attained Phase III tests. The gap in infrastructure has also contributed to the problem since 50% of mid-range hospitals in advanced nations have complained of inadequate GPU servers and IT facilities to use AI technology in real-time.

Opportunities: Multimodal AI models and expanding pharmaceutical partnerships

The development of multimodal AI foundation models dedicated to the field of oncology is an important growth area, involving imagery, genomics, and clinical data into a single framework to help in diagnosis, planning treatment, and discovering drugs at once. On April 2025, Tempus concluded new strategic deals with AstraZeneca and Pathos to create the world's largest multimodal foundation model in oncology, intending to speed up the development of AI-powered drugs and treatments. Such collaboration between AI companies and big pharma companies is the real manifestation of their belief in the ability of multimodal AI to significantly reduce the time needed to develop drugs.

Growing collaboration between technology companies, healthcare institutions, and pharmaceutical firms is opening further opportunity across clinical trial optimization and patient recruitment, areas where AI has already demonstrated measurable efficiency gains. As more cancer centers adopt AI-enabled genomic profiling and real-world data integration, the pool of patients who can be matched to appropriate clinical trials in a fraction of the time traditional recruitment methods require continues to expand. Vendors offering interoperable platforms that plug easily into existing hospital IT systems stand to benefit disproportionately as institutions look to avoid disruptive, ground-up infrastructure overhauls. That acceleration benefits pharmaceutical companies racing to bring new oncology treatments to market and patients seeking access to cutting-edge therapies simultaneously, positioning AI-driven clinical trial infrastructure as one of the more durable growth opportunities in this market through 2035, particularly as more regulatory bodies worldwide begin to formally recognize AI-assisted trial matching as a legitimate part of standard clinical research practice.

Recent Developments:

• 2025: DeepScribe partnered with Flatiron Health to deliver ambient AI documentation solutions tailored for oncology to more than 4,200 providers across Flatiron's clinical network, streamlining clinical note-taking for cancer care teams.

• 2025: Tempus signed expanded strategic agreements with AstraZeneca and Pathos to develop the largest multimodal foundation model in oncology globally, aiming to accelerate AI-powered drug discovery and precision treatment.

• 2025: Siemens Healthcare introduced AI-enabled radiotherapy planning tools that reduce treatment planning time and improve dose accuracy, enhancing outcomes in oncology centers across Europe and Asia.

AI in Oncology Market key players are:

• Azra AI

• IBM

• Siemens Healthcare GmbH

• Intel Corporation

• GE HealthCare

• NVIDIA Corporation

• Digital Diagnostics Inc.

• ConcertAI

• Median Technologies

• PathAI

• MVision AI

• Tempus AI

• Paige AI

• Lunit Inc.

• Qure.ai

• iCAD, Inc.

• Volpara Health Technologies

• Owkin

• Freenome

• Deep Bio

AI in Oncology Market Report Scope: